Fosun Pharma to sell hospital group stake for $124 million

14 March 2025

Chinese pharmaceutical company Fosun Pharmaceutical (SHA: 600196) has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus.

The deal, valued at $124 million, will allow Fosun to sharpen its focus on drug development. Fosun will transfer its 6.6% stake in New Frontier Health, the holding company that owns United Family Healthcare, to Calcite Gem Investments, a Warburg Pincus-backed entity.

The Shanghai-based drugmaker said the proceeds will be used to boost its working capital and reduce outstanding debt.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK